Patent ID: 11890317
Assignee: NOVMETA PHARMA CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 11:
12. A method of inhibiting kidney cell apoptosis in a subject with kidney disease or kidney damage, comprising administering a composition to the subject in an amount effective to inhibit kidney cell apoptosis,
wherein the composition comprises
(a) cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt, as an active ingredient, and
(b) one or more additives selected from the group consisting of sodium starch glycolate, crospovidone, croscarmellose sodium, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, chitosan, guar gum, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, polacrilin potassium, starch, gelatinized starch, microcrystalline cellulose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, sugar, arabic gum, pregelatinized starch, corn starch, powdered cellulose, hydroxypropylcellulose, opadry, sodium starch glycolate, carnauba lead, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, dextrose, sorbitol, and talc, to the subject, and
wherein the kidney disease or kidney damage is chronic.